• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

    8/26/24 8:00:00 AM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRA alert in real time by email

    Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain Thresholds

    MIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is proud to announce a major breakthrough in the treatment of neuropathic pain. A recent pre-clinical study in rats demonstrated that its novel oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose. This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under the same experimental conditions.

    The study, conducted at Pharmaseed Ltd, utilized a nerve ligation model to replicate human neuropathic pain and specifically investigates mechanical allodynia. The results were compelling: low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation. At higher oral dose, Ketamir-2 achieved complete normalization of the pain threshold, representing a 100% reversal of the neuropathic pain signal. These outcomes underscore Ketamir-2's superior efficacy and highlight its potential as a transformative treatment for neuropathic pain, especially compared to oral ketamine, which did not deliver significant pain relief.

    In light of this compelling data, MIRA Pharmaceuticals is conducting additional studies to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain. These studies aim to explore cancer-related indications, which could pave the way for faster regulatory approvals and innovative clinical study designs. MIRA is optimistic that these efforts could demonstrate efficacy in humans as early as 2025.

    "The development of Ketamir-2 as an oral treatment for neuropathic pain is a significant milestone not only for MIRA but for the entire field of neuropsychiatric and neurologic disorder therapies," said Erez Aminov, Chairman and CEO of MIRA Pharmaceuticals. "Neuropathic pain is a debilitating condition that imposes an enormous burden on patients, often leaving them with limited and ineffective treatment options. These findings suggest that Ketamir-2 could offer patients a more accessible, safer, and effective treatment option, potentially transforming the standard of care for neuropathic pain."

    Dr. Itzchak Angel, Chief Scientific Advisor at MIRA Pharmaceuticals, added, "The ability to administer Ketamir-2 orally without the severe psychotropic side effects commonly associated with ketamine is a remarkable achievement. This positions Ketamir-2 as a pioneering treatment in the realm of neuropathic pain, offering hope to patients who have limited options available."

    MIRA Pharmaceuticals continues to advance its research, focusing on scaling production and preparing for the next stages of clinical trials. The company remains committed to bringing safer and more effective treatments to market, with Ketamir-2 at the forefront of its pipeline.

    About MIRA Pharmaceuticals

    MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations.

    In addition, MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. The U.S. Drug Enforcement Administration's scientific review of MIRA-55 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations. Additional information about MIRA Pharmaceuticals is available at: www.mirapharmaceuticals.com

    Ketamir-2 and MIRA-55 are in early-stage preclinical development. There is no assurance that the products will proceed through development or will receive FDA approval for marketing.

    Cautionary Note Regarding Forward-Looking Statements

    This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

    Contact Information

    Helga Moya
    [email protected]
    (786) 432-9792

    SOURCE: Mira Pharmaceuticals, Inc.



    View the original press release on accesswire.com

    Get the next $MIRA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MIRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MIRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aminov Erez bought $8,176 worth of shares (8,700 units at $0.94) (SEC Form 4)

      4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

      5/22/24 5:42:53 PM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Weichselbaum Alan

      3 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

      6/10/25 7:12:54 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Macpherson Edward Clouston

      4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

      12/10/24 5:15:38 PM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Del Giudice Matthew Paul

      4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

      12/10/24 5:15:33 PM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRA
    SEC Filings

    See more
    • MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

      7/2/25 4:06:40 PM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

      6/30/25 7:30:55 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

      6/24/25 4:01:52 PM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

      Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, proudly announces the successful completion of its current Good Laboratory Practice (GLP) preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm no adverse findings, clearing a critical milestone as the Company progresses toward submitting its Investigational New Drug (IND) application by year-end 2024."Our commitment to advancing Ketamir-2 into clinical trials as quickly as possible reflects our strategic focus on generat

      12/10/24 8:30:00 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

      Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment MIAMI, FL / ACCESSWIRE / November 20, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025. The Phase IIa study, planned to start in

      11/20/24 7:44:00 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

      Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in BostonMIAMI, FL / ACCESSWIRE / October 28, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater efficacy than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. These results build on earlier successes across various pain models, further validating Ketamir-2's potential to set a new standar

      10/28/24 7:30:00 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

      Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar

      8/12/24 8:30:00 AM ET
      $MIRA
      $TELO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

      Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA's novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression. MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collabo

      5/21/24 8:45:00 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

      A seasoned pharmaceutical industry executive with over 40 years at the forefront of innovation, including at Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel MIRA Pharmaceuticals' mission to tackle unmet needs in neurologic and neuropsychiatric disorders MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor. Dr. Angel brings over 40 years of preclin

      3/21/24 11:04:00 AM ET
      $MIRA
      Biotechnology: Pharmaceutical Preparations
      Health Care